We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Angion (ANGN) Down on Merger Agreement With Private Biotech
Read MoreHide Full Article
Angion Biomedica Corp. announced that it has entered into a definitive merger agreement with the privately-held biotech, Elicio Therapeutics, wherein the latter will merge with a wholly-owned subsidiary of Angion in an all-stock transaction.
Following the successful completion of the merger, the combined company will continue to operate under the name of Elicio Therapeutics and is likely to trade on the Nasdaq stock exchange under the ticker symbol (“ELTX”). The headquarters of the company will be in Boston, MA.
Shares of Angion were down 30.9% on Tuesday following the announcement of the news. The stock has plunged 68.8% in the past year compared with the industry’s decline of 8.8%.
Image Source: Zacks Investment Research
The combined company’s lead pipeline candidate will be Elicio Therapeutics’ ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors developed with Elicio’s proprietary lymph node-targeting AMP technology. The company will focus on developing immunotherapies based on this AMP technology.
ELI-002 is currently being evaluated in the phase I AMPLIFY-201 study for treating patients who have mKRAS-driven tumors, including pancreatic ductal adenocarcinoma and colorectal cancer. An additional phase Ib/II study on ELI-002 is expected to begin in the second half of the ongoing year.
Per the merger agreement, Elicio stockholders will receive newly issued shares of Angion common stock with the existing stockholders of Angion likely owning around 34.5% while Elicio stockholders will own 65.5% of the newly combined company.
The transaction is expected to close in the second quarter of 2023, subject to customary closing conditions.
Post the merger, the executive team of Elicio, headed by current chief executive officer Robert Connelly, will run the new combined company.
In July 2022, Angion began a process to explore strategic options to enhance shareholder value. As a part of this process, the likely strategic options include a merger, reverse merger, other business combinations, sale of assets, licensing, or other strategic transactions involving Angion.
The company decided to discontinue the development of its pipeline candidate ANG-3070 for all indications as well as stopped most of the other development activities.
Loss per share estimates for Syndax Pharmaceuticals have narrowed 6.5% for 2023 in the past 60 days.
Earnings of Syndax Pharmaceuticals surpassed estimates in three of the trailing four quarters and met the same on the other occasion. SNDX witnessed an earnings surprise of 95.39% on average.
Loss per share estimates for Celularity have narrowed 17.3% for 2023 in the past 60 days.
Earnings of Celularity surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. CELU witnessed an earnings surprise of 51.01% on average.
Loss per share estimates for Arcus Biosciences have narrowed 5.9% for 2023 in the past 60 days.
Earnings of Arcus Biosciences surpassed estimates in two of the trailing four quarters, met the same once and missed on the other occasion. RCUS witnessed an earnings surprise of 56.74% on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Angion (ANGN) Down on Merger Agreement With Private Biotech
Angion Biomedica Corp. announced that it has entered into a definitive merger agreement with the privately-held biotech, Elicio Therapeutics, wherein the latter will merge with a wholly-owned subsidiary of Angion in an all-stock transaction.
Following the successful completion of the merger, the combined company will continue to operate under the name of Elicio Therapeutics and is likely to trade on the Nasdaq stock exchange under the ticker symbol (“ELTX”). The headquarters of the company will be in Boston, MA.
Shares of Angion were down 30.9% on Tuesday following the announcement of the news. The stock has plunged 68.8% in the past year compared with the industry’s decline of 8.8%.
Image Source: Zacks Investment Research
The combined company’s lead pipeline candidate will be Elicio Therapeutics’ ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors developed with Elicio’s proprietary lymph node-targeting AMP technology. The company will focus on developing immunotherapies based on this AMP technology.
ELI-002 is currently being evaluated in the phase I AMPLIFY-201 study for treating patients who have mKRAS-driven tumors, including pancreatic ductal adenocarcinoma and colorectal cancer. An additional phase Ib/II study on ELI-002 is expected to begin in the second half of the ongoing year.
Per the merger agreement, Elicio stockholders will receive newly issued shares of Angion common stock with the existing stockholders of Angion likely owning around 34.5% while Elicio stockholders will own 65.5% of the newly combined company.
The transaction is expected to close in the second quarter of 2023, subject to customary closing conditions.
Post the merger, the executive team of Elicio, headed by current chief executive officer Robert Connelly, will run the new combined company.
In July 2022, Angion began a process to explore strategic options to enhance shareholder value. As a part of this process, the likely strategic options include a merger, reverse merger, other business combinations, sale of assets, licensing, or other strategic transactions involving Angion.
The company decided to discontinue the development of its pipeline candidate ANG-3070 for all indications as well as stopped most of the other development activities.
Zacks Rank & Other Stocks to Consider
Angion currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the biotech sector are Syndax Pharmaceuticals, Inc. (SNDX - Free Report) , Celularity Inc. (CELU - Free Report) and Arcus Biosciences, Inc. (RCUS - Free Report) , all sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Loss per share estimates for Syndax Pharmaceuticals have narrowed 6.5% for 2023 in the past 60 days.
Earnings of Syndax Pharmaceuticals surpassed estimates in three of the trailing four quarters and met the same on the other occasion. SNDX witnessed an earnings surprise of 95.39% on average.
Loss per share estimates for Celularity have narrowed 17.3% for 2023 in the past 60 days.
Earnings of Celularity surpassed estimates in three of the trailing four quarters and missed on the remaining occasion. CELU witnessed an earnings surprise of 51.01% on average.
Loss per share estimates for Arcus Biosciences have narrowed 5.9% for 2023 in the past 60 days.
Earnings of Arcus Biosciences surpassed estimates in two of the trailing four quarters, met the same once and missed on the other occasion. RCUS witnessed an earnings surprise of 56.74% on average.